Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Relmada Therapeutics ( (RLMD) ) has provided an announcement.
On March 9, 2026, Relmada Therapeutics agreed to raise approximately $160 million through a private placement of common stock and pre‑funded warrants to institutional and accredited investors, with closing expected on March 11, 2026, and plans to use the proceeds for working capital, general corporate purposes and advancement of its R&D pipeline. The same day, the company reported 12‑month interim Phase 2 data for NDV-01 in high‑risk non‑muscle invasive bladder cancer showing a 76% complete response rate at 12 months in the overall population and 80% in Bacillus Calmette‑Guérin‑unresponsive patients, with no progression to muscle‑invasive disease or radical cystectomy, supporting a potentially best‑in‑class profile and the launch of a Phase 3 RESCUE registrational program in both second‑line BCG‑unresponsive and adjuvant intermediate‑risk settings starting mid‑2026.
The most recent analyst rating on (RLMD) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Relmada Therapeutics stock, see the RLMD Stock Forecast page.
Spark’s Take on RLMD Stock
According to Spark, TipRanks’ AI Analyst, RLMD is a Neutral.
The score is held back primarily by weak financial performance (no revenue, ongoing large losses, and sustained cash burn with a shrinking equity base). Offsetting this, recent communications were notably positive with strong NDV-01 clinical results, FDA alignment, and a $100M raise extending runway into 2028, while technicals also show improving price momentum; valuation remains difficult to support given negative earnings and no dividend.
To see Spark’s full report on RLMD stock, click here.
More about Relmada Therapeutics
Relmada Therapeutics, Inc. is a clinical‑stage biotechnology company focused on developing transformative therapies for oncology and central nervous system disorders. Its lead candidates include NDV-01, a sustained‑release intravesical gemcitabine/docetaxel formulation for non‑muscle invasive bladder cancer, and sepranolone, both targeting significant unmet medical needs.
Average Trading Volume: 676,516
Technical Sentiment Signal: Hold
Current Market Cap: $326.3M
See more insights into RLMD stock on TipRanks’ Stock Analysis page.